News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
18 Jul 2024
byAudrey Abella
In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).
18 Jul 2024








